Zions Bancorporation N.A. Acquires 4,278 Shares of Haemonetics Co. (NYSE:HAE)

Zions Bancorporation N.A. lifted its holdings in Haemonetics Co. (NYSE:HAE) by 19.5% during the third quarter, HoldingsChannel reports. The firm owned 26,234 shares of the medical instruments supplier’s stock after purchasing an additional 4,278 shares during the period. Zions Bancorporation N.A.’s holdings in Haemonetics were worth $2,109,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Capital Research Global Investors increased its stake in shares of Haemonetics by 2.3% in the first quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock worth $569,690,000 after purchasing an additional 151,183 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Haemonetics by 6.3% in the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock worth $80,972,000 after purchasing an additional 57,665 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Haemonetics by 6,573.6% in the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock worth $70,267,000 after purchasing an additional 836,623 shares during the period. Boston Trust Walden Corp increased its stake in shares of Haemonetics by 13.8% in the third quarter. Boston Trust Walden Corp now owns 809,608 shares of the medical instruments supplier’s stock worth $65,076,000 after purchasing an additional 98,019 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Haemonetics by 75.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier’s stock worth $63,933,000 after purchasing an additional 343,214 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HAE has been the topic of several research reports. Raymond James upgraded Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a research note on Friday, November 8th. BTIG Research initiated coverage on Haemonetics in a research note on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target on the stock. Citigroup lowered their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Barrington Research restated an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a research note on Friday, November 8th. Finally, JMP Securities restated a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a research note on Tuesday, August 13th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $107.88.

Haemonetics Trading Down 1.1 %

HAE stock opened at $90.75 on Friday. Haemonetics Co. has a 1-year low of $70.25 and a 1-year high of $97.97. The firm has a market cap of $4.56 billion, a P/E ratio of 37.66, a P/E/G ratio of 1.43 and a beta of 0.32. The business’s 50 day moving average is $76.90 and its 200-day moving average is $82.71. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping the consensus estimate of $1.09 by $0.03. The business had revenue of $345.50 million for the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. Haemonetics’s revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.99 EPS. Equities analysts anticipate that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.